Cost-effectiveness analysis of metformin with enzalutamide in the metastatic castrate-resistant prostate cancer setting
Enzalutamide (Enza) is an effective treatment for metastatic castrate-resistant prostate cancer (mCPRC). However, Enza is not cost-effective (CE) at willingness to pay (WTP) thresholds from $0-$125 000/quality adjusted life years (QALYs) and is therefore a strain on valuable health care dollars. Metformin (Met) is inexpensive (~$8.00/month) and is thought to improve prostate cancer specific and overall survival compared to those not taking Met. We hypothesized that there must be an added effect Met could provide that would make Enza CE thereby alleviating this financial strain on government health care budgets.
Year of Publication: 2019
Authors: Jordan Hill, Mike Paulden, Christopher McCabe, Scott North, Peter Venner, Nawaid Usmani
Journal Title: The Canadian Journal of Urology
Pages: 10045 - 10053